BCOP Updates 2024: Advances in the Treatment Landscape of Cholangiocarcinoma
There has been a shift in the treatment landscape for metastatic cholangiocarcinoma over the past few years to include immunotherapy and targeted therapies both in the front line setting and in subsequent lines of therapy. This presentation will focus on updates in the front-line treatment of advanced/metastatic cholangiocarcinoma as well as targeted therapies and considerations for treatment.
BCOP Updates 2024: Advances in the Treatment Landscape of Cholangiocarcinoma
Author: Sarah Chehab, PharmD, BCOP
UAN#: 0465-0000-24-085-H01-P
Learning Objectives
- Review the evolution in the treatment landscape for metastatic cholangiocarcinoma, including current first-line therapy recommendations
- Analyze current literature relating to treatment options for patients with metastatic cholangiocarcinoma
- Summarize the role of targeted therapies in the treatment landscape of cholangiocarcinoma
- Examine toxicities of targeted therapies used in the treatment of metastatic cholangiocarcinoma
Get it Now!
Knowledge Course for Pharmacist
Technology requirements: HOPA Learn requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
HOPA is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. In order to claim BCOP credit, you must pass the BCOP Post- Test with a 75% or higher.
All CE hours will be transmitted to the CPE Monitor and BPS within 1-2 weeks of course completion.